Catalent (CTLT) reported $1.03 billion in revenue for the quarter ended December 2023, representing a year- over-year decline of 10.2%. EPS of -$0.24 for the same period compares to $0.67 a year ago. The reported revenue represents a surprise of +1.79% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being -$0.03, the EPS surprise was -700.00%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023. “I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational improvement ...

Key Points Financials, healthcare, utilities and energy often, but not always, perform well when interest rates remain high. Demand for utilities and healthcare remains strong even in a high-rate environment, although the utilities sector has challenges related to capital investment and cost of borrowing. Energy is facing obstacles relating to geopolitical concerns and excess capacity. 5 stocks we like better than Alphabet Large bank stocks such as Berkshire Hathaway Inc. NYSE: BRK.B, JPMorgan Chase & Co. N ...

Catalent’s (CTLT) shares rose 7.2% so far this week. The company’s share price surged following the announcement of its acquisition by Novo Holdings, the parent company of Novo Nordisk (NVO) . Catalent entered into a merger agreement with Novo Nordisk’s parent company on Feb 5. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis. The offered price for each share of CTLT re ...

Proactive新闻团队 - Josh Lamb于2022年毕业于肯特大学历史专业，后加入Proactive担任英国编辑团队的记者[1] - Proactive的新闻团队遍布全球主要金融和投资中心，设有办事处和工作室[2] Proactive的专业领域 - Proactive是中小市值市场的专家，同时也关注蓝筹公司、大宗商品和更广泛的投资故事，致力于激发和吸引有动力的私人投资者[3] - Proactive团队提供市场上跨领域的新闻和独特见解，包括生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术[4]

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: ZeroFox has agreed to be acquired by Havel ...

Catalent (CTLT) shares rallied 9.7% in the last trading session to close at $59.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.2% gain over the past four weeks. The sharp upsurge in Catalent's shares can be attributed to the announcement of a deal where the company will be acquired by Novo Holdings for $63.50 per share in cash. The deal puts an enterprise value of $16.5 billion on Catalent. This maker ...

Shares of Catalent (CTLT 9.74%) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent company of Novo Nordisk (NVO 4.01%). Novo Nordisk is bringing Catalent under its wing In a press release Monday, Catalent announced it had agreed to be acquired by Novo Holdings for $63.50 per share in cash -- a 16.5% premium from Friday's closing price and a nearly 48% premium to its 60-day volume- weighted average ...

收购新闻 - 诺和诺德控股公司将以115亿美元收购Catalent Inc，以满足对减肥药Wegovy的强劲需求[1] 股票表现 - Catalent股票自11月中旬以来一直在上涨，但仍未能填补4月份由于Danaher收购失败而导致的空缺[3] 期权市场活跃 - Catalent股票的期权市场异常活跃，成交量是平均水平的11倍，2月60美元看涨期权最受欢迎[4] 空头情况 - Catalent股票的空头利息占可用流通股的6.1%，如果按照平均交易速度计算，空头需要近五天才能平仓[5]

Catalent股价飙升 - Catalent股价飙升，因挪威诺德主要股东Novo Holdings以165亿美元现金收购这家注射器制造商[1] - Catalent股价在签署交易后早盘交易中飙升10%，Novo Nordisk的控股股东以63.5美元每股的价格全现金收购了Catalent的所有未流通股份[3] 收购扩大生产能力 - 收购扩大了挪威诺德的生产能力和供应灵活性，特别是对其减肥药Wegovy[2] - Catalent总部位于新泽西州萨默塞特，是挪威诺德流行的减肥药Wegovy注射笔的主要制造商[5] 交易细节 - 交易完成后，挪威诺德将以110亿美元的债务交易从Novo Holdings购买Catalent的三个“填充-完成”站点，这些站点位于意大利、比利时和美国，并与Novo Nordisk有持续合作[6] - 挪威诺德表示，购买这三个站点可能会对2024年和2025年的运营利润增长产生“低个位数的负面影响”[8] 交易预期 - Novo Holdings和Catalent表示，他们预计交易将在年底前完成，需获得股东和监管机构的批准[8]